左悦琪，1991年12月生，中共党员，理学博士，现任西安医学院基础与转化医学研究所副教授。主要从事肿瘤分子药理研究及新型抗肿瘤小分子药物开发，同时开展新型蛋白功能调控小分子的设计及应用研究。
（1）国家自然科学基金青年基金项目，22407109，兼具逆转转录抑制及诱导蛋白乙酰化功能的新型BCL6靶向嵌合体的发现及机制研究，2025/01-2027/12，30万元，在研，主持。
（2）陕西省自然科学基础研究计划青年项目，2023-JC-QN-0877，PI3Kδ/BRD4双靶点抑制剂的发现及抗非霍奇金淋巴瘤活性研究，2023/01-2024/12，5万元，在研，主持。
（4）西安医学院博士科研启动基金，基于克服TMZ耐药的EZH2/BCL6双靶点抑制剂的发现及抗胶质母细胞瘤活性研究，2023/11-2025/11，5万元，在研。
（5）国家卫生计生委“重大新药创制”国家科技重大专项，2017ZX09201006-011，基于优良DAA组合用药治疗丙肝的新型复方SKLB-FA的开发，2017/01-2020/12，延期至2021/06，534.73万元，结题，参加。
[1] Yueqi Zuo, Ke Zhang, Mengchi Zhang, Ting Wang, Yongxia Zhu, Ningyu Wang, Xingchun Gou. Polymerase theta (Polθ) and cancer: Role in tumor progression and potential as a therapeutic target. European Journal of Medicinal Chemistry. 2025;302:118283.
[2] Yueqi Zuo*, Yongxia Zhu*, Peng Luo, Nan Huang, Kun Yao, Ke Zhang, Ningyu Wang#, Xingchun Gou#. Design, synthesis, and biological evaluation of novel PI3Kδ/HDAC6 dual inhibitors for the treatment of non-Hodgkin’s lymphoma. European Journal of Medicinal Chemistry. 2025;296:117852.
[3] Yongxia Zhu, Tong Xia, Da-Qian Chen, Xia Xiong, Lihong Shi, Yueqi Zuo#, Hongtao Xiao#, Li Liu#. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance. Drug Resistance Updates. 2024;72:101016.
[4] Yueqi Zuo*, Yongxia Zhu*, Zhihao Liu, Yong Xia, Ying Xu, Cuiting Peng, Luoting Yu#, Ningyu Wang#. BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression. American Journal of Cancer Research. 2021;11:215-235.
[5] Yueqi Zuo*, Rong Hu*, Wanli Wang, Yongxia Zhu, Ying Xu, Luoting Yu, Zhihao Liu, Ningyu Wang#. Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin’s lymphoma. Bioorganic Chemistry. 2020;105:104344.
[6] Yueqi Zuo*, Ningyu Wang*, Yongxia Zhu, Li Liu, Kunjie Xiao, Lidan Zhang, Chao Gao, Zhihao Liu, Cuiting Peng, Kai Ran, Hong Tang, Luoting Yu#. A new series of HCV inhibitors based on 2-(thieno[2,3-b]pyridin-2-yl)-1,3,4-oxadiazole scaffold. RSC Advances. 2016;6:40277-40286.
[7] Yongxia Zhu*, Yueqi Zuo*, Lijuan Chen, Shasha Bian, Jiayu Jing, Cailin Gan, Xiuli Wu, Hongyao Liu, Xingping Su, Wanglai Hu, Yuqi Guo, Yue Wang, Tinghong Ye. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. Biochemical Pharmacology. 2019;169:113610.
[8] Ningyu Wang*, Yueqi Zuo*, Rong Hu, Wanli Wang, Yongxia Zhu, Ying Xu, Luoting Yu, Zhihao Liu. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors. Bioorganic & Medicinal Chemistry Letters. 2020;30:127479.
